Elevation of liver function tests (LFTs) has been noted in patients treated with sirolimus. However, in the United States [1] and global phase 3 trials, [2] elevation of LFTs, specifically of AST ...
Only two months after Centessa dropped its lead asset due to a patient experiencing elevated liver enzymes, the biotech has now culled an early-stage candidate over a similar adverse event. Centessa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results